The Brand Name ALENFAST-50 Has Generic Salt :: TAPENTADOL 

ALENFAST-50  Is From Company ALEMBIC Priced :: Rs. 105

ALENFAST-50 have TAPENTADOL is comes under Sub class Opioid Analgesics of  Main Class Nervous System

Main Medicine Class:: Nervous System  Sub Medicine Class :: Opioid Analgesics 

Indications for Drugs ::

Diabetic neuropathy, Musculoskeletal pain

Drug Dose ::

Moderate-to-Severe Pain Acute (immediate-release tablet or oral solution) 50-100 mg PO q4-6hr PRN; not to exceed 700 mg on day 1 and 600 mg/day thereafter. Chronic (extended-release tablet) 50-250 mg PO q12hr PRN; not to exceed 500 mg/day. Opioid-naive patients: 50 mg PO q12hr; titrated to optimal dosage as needed; not to exceed 500 mg/day Diabetic Peripheral Neuropathy Treatment of pain associated with diabetic peripheral neuropathy when continuous, around-the-clock opioid analgesic is needed for extended period Extended release: 50 mg PO q12hr initially; titrated to balance individual tolerance with efficacy; typical range, 100-250 mg PO q12hr. Renal impairment CrCl >30 mL/min : Dosage adjustment not required CrCl <30 mL/min: Not recommended Hepatic impairment Mild: Dosage adjustment not required Moderate: 50 mg immediate release q8hr initially; dosing frequency not to exceed 3 times daily; alternatively, 50 mg PO q24hr extended release; not to exceed 100 mg/day Contraindication ::

Hypersensitivity (eg, anaphylaxis, angioedema) Significant respiratory depression Acute or severe asthma Hypercarbia in unmonitored setting or in absence of resuscitative equipment Paralytic ileus Coadministration with monoamine oxidase inhibitors (MAOIs) or use within 14 days

Drug Precautions ::

Opioid REMS FDA now requires risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid analgesics REMS strongly encourages prescribers to complete REMS-compliant education program and to counsel patients regarding safe use, risks, storage, and disposal of ER/LA opioids Limitations of use ER/LA opioids are intended only for management of moderate-to-severe pain when continuous, around-the-clock opioid analgesic is needed for extended period ER/LA opioids are not intended for PRN use, acute pain, or postoperative pain (unless patient is already receiving long-term opioid therapy before surgery or postoperative pain is expected to persist for extended period Abuse potential Druig is controlled substance with abuse potential; assess patient’s risk for opioid abuse or addiction (including alcohol) before prescribing Assess mental illness (eg, major depressive disorder) Routinely monitor for signs of misuse, abuse, and addiction during treatment Life-threatening respiratory depression Respiratory depression, including fatal cases, may occur even when drug is used at recommended doses without misuse or abuse; proper dosing titration is essential and should be prescribed by healthcare providers knowledgeable in use of opioids and pain relief Follow administration instructions for ER/LA opioids regarding swallowing whole (ie, do not chew, crush, or dissolve tablet) to avoid too-rapid release and absorption of potentially fatal dose Accidental exposure Accidental ingestion, especially in children, can result in fatal overdose of opioid analgesic Alcohol interaction Instruct patients not to consume alcoholic beverages or use alcohol-containing drug products while taking morphine Coingestion of alcohol with opioid analgesics may increase plasma opioid levels and potentially result in fatal overdose

Drug Side Effects ::

>10% Nausea (30%) Dizziness (24%) Vomiting (18%) Somnolence (15%) 1-10% (selected) Constipation (8%) Pruritus (5%) Xerostomia (4%) Fatigue (3%) Hyperhidrosis (3%) Anorexia (2%) Dyspepsia (2%) Insomnia (2%) Postmarketing Reports Anaphylaxis, angioedema, anaphylactic shock Psychiatric disorders: Hallucinations, suicidal ideation, panic attack Nervous system disorders: Headache Gastrointestinal disorders: Diarrhea Cardiac disorders: Palpitations

Pregnancy category ::

3

Drug Mode of Action ::  

Mu-opioid agonist; inhibits ascending pain pathways, thus altering response to pain; produces analgesia, respiratory depression, and sedation; also inhibits reuptake of norepinephrine, which also affects ascending pain pathways.

Drug Interactions ::

Potential severe adverse effects w/ MAOIs. CNS-active drugs; other serotonergic agents (including triptans, SSRIs, other SNRIs, lithium, sibutramine, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine or St. John’s wort), drugs which impair serotonin (eg linezolid & methylene blue) or serotonin precursors (eg tryptophan supplements). Increased risk of QTc prolongation &/or ventricular arrhythmias w/ some antipsychotics & antibiotics. Decreased AUC & Cmax of indinavir. Increased AUC & Cmax of haloperidol. Increased plasma conc w/ ketoconazole. Increased plasma conc & reduced BP-lowering effect of metoprolol. Increased AUC of risperidone. Reduced metabolism w/ CYP2D6 inhibitors. Increased venlafaxine levels w/ CYP3A4 inhibitors.